sitefansalaran Drug Information

A major new study reveals that combining the weight-loss drug tirzepatide with menopause hormone therapy leads to significantly greater fat loss in postmenopausal women. Women using both therapies saw an average weight loss of 17%—compared to just 14% with tirzepatide alone—and were more than twice as likely to lose 20% or more of their body weight. Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Postmenopausal Women Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. “These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” said Regina Castaneda, M.D., research fellow for the Division of Endocrinology at the Mayo Clinic in Jacksonville, Fla. “Previous studies of the medication semaglutide found similar results. Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these two classes of medications.” Why Menopause Makes Weight Loss Harder Menopause-related hormonal changes often result in increased abdominal fat, decreased muscle mass, and altered...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with the menopause. When oestrogen levels drop during menopause, certain brain cells become overactive and interrupt the body’s ability to control temperature, which leads to hot flushes and night sweats. Elinzanetant is a new non-hormonal medication which works by calming these signals in the brain, helping bring the body’s temperature control back into balance. It may also help improve sleep problems that often come with menopause. This medicine is administered in capsule form, to be taken orally. Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said: “Hot flushes and night sweats associated with menopause can have a significant negative impact on quality of life. “We are therefore pleased to announce our approval of elinzanetant, which has met the MHRA’s standards for safety, quality and effectiveness. “Elinzanetant offers a non-hormonal alternative for those who may not be able to, or prefer not to, take hormone-based therapies. As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used.” Elinzanetant’s approval is based...